Beckman Coulter
This article was originally published in The Gray Sheet
Executive Summary
Firm acquires full rights for Nephromics' preeclampsia assay development program, currently in clinical testing for use with Beckman Coulter's UniCel Dxl and Access immunoassay systems and UniCel DxCi chemistry-immunoassay work cells. In 2005, the companies inked a licensing agreement giving Beckman Coulter non-exclusive access to the program. Deal also includes rights to acquire Nephromics' worldwide diagnostic assets. According to Beckman Coulter, there are no specific in vitro diagnostic tests for preeclampsia, a hypertensive disorder that occurs in up to 10% of pregnancies. The firm says it hopes to launch the tests in 2009
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.